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Abstract 
Nitric oxide (NO) has a vast range of biological functions; exhibiting tumoricidal and 
antimicrobial properties while also playing a role in angiogenesis, platelet adhesion, and 
inflammatory responses. Macromolecular scaffolds capable of storing and releasing NO have the 
potential to be used as antimicrobial agents to protect populations more prone to bacterial infection, 
such as people who suffer from cystic fibrosis (CF). Alginate, an anionic biopolymer composed 
of mannuronic acid and guluronic acid residues, represent an ideal NO-releasing vehicle due to 
low cytotoxicity, simple modification process, and water solubility even at high molecular weights 
(200-500 kDa). Herein, we report a systematic study to examine the antibacterial properties of 
different molecular weight alginate against planktonic Pseudomonas aeruginosa and 
Staphylococcus aureus, two of the most common pathogens present in CF patients. Lower 
molecular weight (2 - 5 kDa) NO-releasing alginate was found to have improved bactericidal 
efficacy against Pseudomonas aeruginosa, requiring lower NO doses to achieve bacterial killing 
compared to the conventional antibiotic - tobramycin. However, NO-releasing alginates’ 
bactericidal efficacy against S. aureus did not exhibit a clear dependency on molecular weight. 
 
Introduction 
Cystic fibrosis (CF) is an autosomal disorder that affects over 30,000 individuals in the 
United States.1,2 Primarily, this disease affects the lungs by impeding mucociliary clearance from 
the airways,3 causing buildup of a thick, dehydrated and immobile mucus layer. The accumulation 
of this thick stagnant mucus provides a suitable environment for bacterial colonization and 
increases patients’ susceptibility to pathogens such as Pseudomonas aeruginosa and 
Staphylococcus aureus.4-7 Bacterial infection by these two species pose a great challenge to human 
health. These bacteria could proliferate throughout the airway, leading to acute pulmonary 
exacerbation, or develop into biofilm colonies. Biofilms are particularly problematic due to the 
formation of an exopolysaccharide matrix, which protects it from host immune response and 
antibiotics. As such, biofilm typically require ~1000 times more antibiotic dose to eliminate 
compared to planktonic bacteria. No cure currently exists for CF, but treatments can improve 
quality of life for patients by combating chronic bacterial infection. Unfortunately, bacterial 
species have developed potential cellular mechanism (e.g., self-alteration of cell membrane targets 
and the use of pumps to reduce internal concentration of antibiotics)8 that minimize the effects of 
traditional antibiotics such as tobramycin and methicillin. Specifically, multiple drug-resistant 
Pseudomonas aeruginosa (MDR-PA) and methicillin-resistant Staphylococcus aureus (MRSA) 
infections present a difficult challenge for traditional treatment methods.3,9 Therefore, novel 
antibacterial agents that can effectively eliminate planktonic bacteria responsible for chronic 
infection in CF are greatly needed in the fight against emerging antibiotic-resistant pathogens.10  
Nitric oxide (NO), an endogenously produced free radical, acts as a mediator of 
vasodilation and plays a key role in mammalian immune response to pathogens. The production 
of NO is significantly reduced in bronchial epithelium of people suffering from cystic fibrosis, 
which contributes to severe inflammation and repeated bacterial infection in the lungs. Nitric oxide 
also function as a broad-spectrum antibacterial agent capable of eradicating both planktonic 
bacteria and biofilms. The mechanism for NO’s antibacterial action is primarily through the 
formation of reactive NO byproducts (e.g., peroxynitrite and dinitrogen trioxide) that cause 
oxidative and nitrosative damage to microbial DNA and membrane structures.11-15 The multiple 
mechanisms by which NO exerts its antibacterial effects also makes it unlikely for bacterial species 
to develop resistance.16 Due to its antibacterial properties and endogenous production, NO is a 
good candidate for use as a therapeutic against chronic bacterial infections in CF lungs. 
The hazards of gaseous NO such as high reactivity and toxicity concerns has led to the 
development of N-diazeniumdiolate NO donors. The use of N-diazeniumdiolates over gaseous NO 
is particularly attractive due to its ability to spontaneously release NO in aqueous solution at 
physiological pH.30 Alginate, an abundant naturally-derived biopolymer, has been widely used in 
numerous biomedical applications (e.g., drug delivery, and wound dressings).17-19 As a naturally 
occurring anionic polysaccharide, alginate consist of 1,4-linked α-L-guluronic acid and β-D-
mannuronic acid units.20,21 Alginates represent an ideal NO-delivering scaffold due to its 
biocompatibility, favorable toxicity profiles, and water solubility even at high molecular weight 
(critical property for in situ release).25-27 Nitric oxide-releasing biomacromolecules, such as 
alginate, are preferred over small molecule NO donors due to the latter’s precursor toxicity when 
larger concentrations are required to elicit bactericidal action.28-30 
Herein, we describe the functionalization of alginates of various molecular weight and the 
subsequent modification with N-diazeniumdiolates, producing an anionic NO-releasing 
biopolymers. The bactericidal action of the alginates was examined with respect to NO-releasing 
kinetics, total NO storage, and molecular weight. 
To summarize, the goal of my research is to: 
1) Synthesize and characterize secondary amine-modified alginate of various molecular 
weight 
2) Characterize the NO storage capacity and NO-releasing kinetic of the different molecular 
weight alginates 
3) Examine the bacterial efficacy of NO-releasing alginates against Pseudomonas aeruginosa 




Alginic acid sodium salt from brown algae (low viscosity), bis(3-aminopropyl) amine 
(DPTA), 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimide hydrochloride (EDC), N-
hydroxysuccinimide (NHS) were purchased from Sigma-Aldrich (St. Louis, MO). Common 
laboratory salts and solvents were purchased from Fischer Scientific (Fair Lawn, NJ). Unless 
otherwise specified, all chemicals were used as received without further purification. Tryptic soy 
broth (TSB) and tryptic soy agar (TSA) were obtained from Becton, Dickinson, and Company 
(Franklin Lakes, NJ). Pseudomonas aeruginosa (P. aeruginosa; ATCC #19143), and 
Staphylococcus aureus (S. aureus; ATCC #29213) were obtained from American Type Tissue 
Culture Collection (Manassas, VA). Argon (Ar), carbon dioxide (CO2), nitrogen (N2) gas cylinders 
were purchased from Airgas National Welders (Raleigh, NC). Pure NO gas (99.5%) was obtained 
from Praxair (Sanford, NC). Distilled water was purified to a resistivity of 18.2 MΩ•cm and a total 
organic content of ≤ 6 ppb using a Millipore MilliQ UV Gradient A10 System (Bedford, MA). 
 
Instrumentation 
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker (600 
MHz) spectrometer. Viscometry measurements were taken using an Ubbelohde Viscometer.  
 
Oxidative degradation of commercial alginate 
Alginate was degraded to lower molecular weight oligosaccharides by oxidative 
degradation following previously published protocols.30 Alginate was first dissolved in hydrogen 
peroxide (50 mL) and stirred at high temperatures in an oil bath. Reaction parameters (i.e., H2O2 
concentration, temperature, and time of reaction) were varied to obtain a range of alginate 
molecular weights (Table 1). The degraded sample was precipitated from the solution using 
ethanol, collected via centrifugation, washed copiously with ethanol, and dried in vacuum to yield 
a white powdery solid. Intrinsic viscometry data was converted to molecular weight using the 
Mark-Houwink equation where k = 0.0073 cm3/g and a = 0.92.31 Viscometry measurement 
revealed the molecular weight of the starting alginate material, as received, was 283 kDa (Alg300), 
the degraded alginates’ molecular weight was also measured using the same process (Table 1). 
 
Synthesis of secondary amine functionalized alginate (AlgMW-DPTA) 
Commercial and degraded alginate samples were modified with dipropyltriamine (DPTA) 
through covalent amide bond formation between the carboxylic acid moieties of alginate and the 
primary amines of the alkyl amine (Scheme 1)30. Alginate (100 mg) was dissolved in 10 mL of 
phosphate buffered saline (PBS; 10 mM, pH 6.5) together with a 2:1 molar ratio of 1-ethyl-3-(3-
(dimethylamino)propyl)-carbodiimide hydrochloride (EDC) and a 2:1 molar ratio of N-
hydroxysuccinimide (NHS) with respect to the carboxylic moieties of the alginate scaffold. The 
resulting solution was allowed to mix at room temperature for 30 min before adding a 4:1 molar 
ratio of DPTA with respect to the carboxylic acid groups of the alginate scaffold to the reaction 
solution. After 24 h at room temperature, the amine-modified alginates were precipitated in 
methanol, collected via centrifugation, washed with methanol, and dried in vacuum to yield a white 
solid. 
Representative 1H NMR of alginate and the DPTA-modified alginates included the 
following peaks: 
Alg300, Alg10, Alg5, and Alg2: 1H NMR (600 MHz, D2O, δ) 3.60−4.05 
(OCHCH(OH)CH(OH)), 4.30 (OCHCH(OH)CH(OH)), 4.50−4.60 (NHCOCH), 4.90 
(OCH(CHOH)O). 
Alg300-DPTA, Alg10-DPTA, Alg5-DPTA, and Alg2-DPTA: 1H NMR (600 MHz, D2O, 
δ) 1.60−1.80 (CH2CH2CH2NHCH2CH2CH2NH2), 2.60−2.30 (CH2CH2CH2NHCH2CH2CH2NH2), 
2.80−3.10 (CH2CH2CH2NHCH2CH2CH2NH2), 3.60−4.05 (OCHCH(OH)-CH(OH)), 4.30 
(OCHCH(OH)CH(OH), 4.50−4.60 (NHCOCH), 4.90 (OCH(CHOH)O). 
Representative 13C NMR of alginate and the DPTA-modified alginates included the 
following peaks: 
 Alg300, Alg10, Alg5 and Alg2: 13C NMR (600 MHz, D2O, δ) 65.0−80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 175.0 (CHC(O)). 
 Alg300-DPTA, Alg10-DPTa, Alg5-DPTA, and Alg2-DPTA: 13C NMR (600 MHz, D2O, 
δ) 26.9−29.5 (C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 37.6−46.0 
(C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 65.0−80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)). 
Scheme 1. Synthesis of secondary amine functionalized alginate via EDC/NHS reaction30 
 
Synthesis and characterization of NO-releasing alginates 
Secondary amine-modified alginate scaffolds (45 mg) were dissolved in 50 mM NaOH (3 
mL) in a 1-dram glass vial to form N-diazeniumdiolate NO donors. The open vials were placed in 
a stainless steel reactor and stirred continuously using a magnetic stir bar. Oxygen was purged 
from the vessel with argon (10 s, 7 bar) three times followed by three additional long purges with 
argon (10 min, 7 bar). The vessel was then pressurized to 10 bar with NO gas and allowed to react 
for 3 d (Scheme 2). After 3 days, the argon purges were repeated to remove excess NO. The NO-
releasing alginates were then precipitated in methanol, collected by centrifugation, dried overnight 
in vacuum, and stored in vacuum sealed bags at -20°C as a dry powder. 
 




10 bar NO 
50 mM NaOH 
Nitric oxide release was evaluated in real-time using a Sievers 280i Chemiluminescence 
NO analyzer (NOA; Boulder, CO). In a typical measurement, NO-releasing alginates (~1 mg) were 
dissolved in 30 mL of PBS (10 mM, pH 7.4, 37°C). The solution was purged with nitrogen gas at 
a flow rate of 70 mL/min to carry liberated NO from the solution to the analyzer. Nitric oxide 
analysis was terminated when NO levels fell below the detection limit of the instrument, 10 ppb 
of NO/mg of alginate. 
 
Planktonic Bactericidal Assays 
P. aeruginosa and S. aureus bacterial colonies from frozen (-80°C) stock were inoculated 
in 3 mL of TSB overnight at 37°C. The colonies were recultured in fresh TSB (50 mL) to a 
concentration of 108 colony forming units per mL (CFU/mL). Aliquots of bacterial cultures were 
suspended in PBS, and diluted to 106 CFU/mL. Weighed samples of NO-releasing alginates with 
various molecular weights were added to a 1-dram vial. Corresponding volumes of 106 CFU/mL 
bacteria were then added to obtain a range of alginate concentrations (0.25 - 32 mg/mL). These 
solutions were incubated for 4 h at 37°C. Blanks or untreated bacterial solutions were included in 
each experiment to ensure bacteria viability over the duration of the experiment. Following 
treatment, the bacterial solutions were spiral plated on TSA plates using an Eddy Jet spiral plater 
(IUL; Farmingdale, NY). The minimum bactericidal concentration after a 4 h exposure period 
(MBC4h) was defined as the minimum concentration required to achieve a 3-log reduction (i.e., 
99.9% decrease) in bacterial viability relative to the untreated cells. The limit of detection for this 
method is 2.5×103 CFU/mL. The corresponding NO dose was calculated by multiplying the MBC4h 
of alginate samples with the measured NO release in PBS over the 4 h window. 
 
Results and Discussion 
Oxidative degradation of alginate 
 Commercial alginate (Alg300) was successfully degraded to alginate oligosaccharides of 
various molecular weight following the previously published protocols.31 The resulting alginate 
oligosaccharides ranged from 2 kDa to 10 kDa (Table 1). 
 
Table 1. Oxidative degradation of alginate to various molecular weights 








Alg2 30 2 85 2.21 ± 0.23 
Alg5 15 1 85 4.68 ± 1.20 
Alg10 15 1 70 10.77 ± 0.57 
 
The oxidative degradation process involved altering the reaction parameters of reaction 
temperature, reaction time, and hydrogen peroxide concentration. Increasing any of the three 
parameters led to a decrease in oligosaccharide molecular weight. 
 
Synthesis of N-diazeniumdiolate-functionalized alginate 
Following the secondary amine functionalization protocol (Scheme 1), various molecular 
weight alginates were charged with high pressures of NO (10 bar) in basic aqueous solution (50 
mM NaOH) to allow formation of N-diazeniumdiolate NO donors. Nitric oxide-releasing profiles 
of the N-diazeniumdiolate-functionalized alginates in PBS (pH 7.4) are reported in Table 2. The 
difference in total NO release was not significantly different between the NO-releasing alginates 
of various molecular weights (~0.4 µmol/mg). The molecular weight of the alginate, however, 
dramatically influenced NO-release kinetics. Lower molecular weight NO-releasing alginate (2 - 
5 kDa) released NO much more rapidly than NO-releasing alginate of larger molecular weight (10 
- 300 kDa). The total release duration as well as the half-life of NO release all decreased as 
molecular weight decreased. In addition, the high flux and larger four hour NO total of the lower 
molecular weight alginate suggests that more NO is available over the course of the standard 
duration for the bactericidal assays. 
 
Table 2. Nitric oxide storage capacity and release kinetics of N-diazeniumdiolate modified 
alginates 
Sample t[NO] (µmol/mg) t1/2 (h) td (h) t[NO]4h (µmol/mg) 
Alg2 - DPTA/NO 0.45 ± 0.01 1.1 ± 0.0 7.3 ± 0.90 0.43 ± 0.04 
Alg5 - DPTA/NO 0.48 ± 0.02 1.2 ± 0.1 8.7 ± 0.50 0.45 ± 0.10 
Alg10 - DPTA/NO 0.37 ± 0.02 3.5 ± 0.8 10.6 ± 2.6 0.32 ± 0.04 
Alg300 - DPTA/NO 0.42 ± 0.04 3.4 ± 0.6 16.1 ± 2.9 0.23 ± 0.01 
 
Of note, negligible NO release was observed for alginates modified with primary amine 
and amide functional groups as previous reported.30 This indicates that neither primary amine nor 
amide groups are able to form the N-diazeniumdiolate NO donor. 
 
Antibacterial action against planktonic bacteria 
Antibacterial activity of control and NO-releasing alginates was evaluated against P. 
aeruginosa and S. aureus, two prevalent pathogens associated with infections in CF.3-5 Bacterial 
viability assays were performed under static conditions to determine the minimum bactericidal 
concentration of the sample required to elicit a 3-log reduction (i.e., 99.9% killing) in bacterial 
viability over 4 h (MBC4h). Non-NO-releasing alginate control did not elicit any bactericidal 
activity up to 16 mg/mL against both pathogens. Against P. aeruginosa, NO-releasing alginates 
achieved a 3-log reduction against at low concentrations (≤ 2 mg/mL). In particular, Alg2 - 
DPTA/NO achieved the lowest MBC4h (0.25 mg/mL) and the lowest NO dosage (0.11 µmol/mL). 
Antibacterial action proved to be molecular weight dependent, with lower molecular weight 
alginate demonstrating enhanced bactericidal efficacy. This is likely due to the molecular weight 
of the degraded alginate allowing for better association with the bacterial membrane, thus 
improving targeted NO release against P. aeruginosa compared to higher molecular weight 
systems. This follows similar trends previously reported in literature for NO-releasing materials.30 
Another reason is the higher initial NO flux and higher t[NO]4h associated with lower molecular 
weight NO-releasing alginates. That is, a greater alginate concentration was needed to achieve 
similar NO doses for the higher molecular weight system. 
 
Table 3. Bactericidal efficacy of NO-releasing alginates against Pseudomonas aeruginosa 
compared to Tobramycin 
Scaffolds MBC4h (mg/ml) t[NO]4h (µmol/mg) NO/Drug dose (µmol/ml) 
Alg 2 – DPTA/NO 0.25 0.43 ± 0.04 0.11 ± 0.01 
Alg 5 – DPTA/NO 0.25 0.45 ± 0.10 0.11 ± 0.03 
Alg 10 – DPTA/NO 0.50 0.32 ± 0.04 0.16 ± 0.02 
Alg 300 – DPTA/NO 2.00 0.23 ± 0.01 0.46 ± 0.02 
Tobramycin 0.13 - 0.27 
 
The ability of NO-releasing alginates to kill S. aureus was significantly reduced compared 
to its efficacy against P. aeruginosa, as indicated by the higher MBC4h and NO dose. The thicker 
peptidoglycan layer of S. aureus likely decreases the diffusion of NO into the bacterium, 
necessitating larger doses of the macromolecule to achieve 3-log reduction in bacterial viability. 
P. aeruginosa, a Gram-negative bacteria, has a more lipid-rich outer membrane and thinner 
peptidoglycan sheets, thus increasing its susceptibility to NO and other permeating 
antimicrobials.30 In addition, the bactericidal efficacy of NO-releasing alginate (5-300 kDa) 
against S. aureus were found to be equivalent. However, at a molecular weight lower than 5 kDa, 
the NO dose required to achieve 3-log reduction increases to 4 mg/ml. Future studies will explore 
why Alg5 - DPTA/NO was most efficient against S. aureus. 
Compared to the commercial antibiotic tobramycin, the NO-releasing alginate 
oligosaccharides required lower NO dose to exhibit bactericidal action. This signifies that NO-
releasing alginate is a more efficient therapeutic against P. aeruginosa infections than the 
traditional tobramycin. The bactericidal action of NO-releasing alginate was less efficient than that 
of tobramycin against S. aureus. This is likely due to the thicker peptidoglycan layer of the S. 
aureus that hinders NO diffusion. 
 
Table 4. Bactericidal efficacy of NO-releasing alginates against Staphylococcus aureus compared 
to Tobramycin 
Scaffolds MBC4h (mg/ml) t[NO]4h (µmol/mg) NO/Drug dose (µmol/ml) 
Alg 2 – DPTA/NO 4.00 0.43 ± 0.04 1.74 ± 0.16 
Alg 5 – DPTA/NO 2.00 0.45 ± 0.10 0.90 ± 0.20 
Alg 10 – DPTA/NO 4.00 0.32 ± 0.04 1.28 ± 0.16 
Alg 300 – DPTA/NO 4.00 0.23 ± 0.01 0.92 ± 0.04 




Commercial alginate (Alg300) was successfully degraded to oligosaccharides of various 
molecular weights (2 - 10 kDa). The alginate oligosaccharides were successfully modified with 
DPTA and functionalized with N-diazeniumdiolate NO donors. The NO totals for the alginates did 
not vary significantly between different molecular weights (2 - 300 kDa). However, the NO-
releasing kinetics were determined to dramatically change as a function of molecular weight. 
Lower molecular weight alginates led to lower total NO-releasing duration (~9 h) and shorter 
release half-lives (~1 h). As a consequence, the lower molecular weight NO-releasing alginates 
had a larger burst of NO release during a four hour bacterial exposure assay, allowing for higher 
total NO released at 4 h. 
The antibacterial activity was found to be molecular weight dependent against P. 
aeruginosa with Alg2-DPTA/NO requiring the least alginate concentration and NO dose to elicit 
bactericidal action. In addition, NO-releasing alginate oligosaccharides (2 kDa, 5 kDa, and 10 kDa,) 
required lower NO dose compared to tobramycin, suggesting that the NO-releasing alginates are 
more efficacious against P. aeruginosa infections. Higher alginate concentrations and NO doses 
were needed to elicit bactericidal action against S. aureus than P. aeruginosa. No dependence on 
biopolymer molecular weight was found on the antibacterial activity of NO-releasing alginate 
against Gram positive bacteria such as S. aureus. 
The antibacterial efficacy of NO-releasing alginates as potential CF therapeutics lies in its 
ability to combat the increasingly prevalent drug resistant strains of pathogens. Future work will 
focus on the determination of the bactericidal efficacy of NO-releasing alginates against other CF-
relevant pathogens, especially drug resistant strains (e.g., MDR-PA and MRSA). This will help 
solidify NO-releasing alginate’s positon as an attractive alternative to traditional treatments. 
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